Kiniksa launches Phase 2b clinical trial of abiprubart in Sjögren’s
Kiniksa Pharmaceuticals has launched a Phase 2b clinical trial to test its injectable therapy abiprubart against a placebo in people with Sjögren’s syndrome. The trial, mainly designed to assess the treatment’s effects on disease severity, is expected to involve about 201 Sjögren’s patients. Kiniksa reports that the trial…